Mumbai-based B2B pharma platform Fundly.ai has raised $4.9 million, led by existing investors Accel and Multiply Ventures, to scale its commerce, payments, and credit business across India's pharmaceutical supply chain.
Inside the Deal
- Round size: $4.9 million (equity + venture debt)
- Venture debt component: $900,000 from Alteria Capital
- Lead investors: Accel, Multiply Ventures (both existing backers)
- Other participants: Rajeev Ahuja (ex-RBL Bank Executive Director), angel investors
- Financial terms: Undisclosed
- Previous round: $3 million seed in 2023, also led by Accel
From Pharma Lender to Full-Stack B2B Platform
Fundly didn't set out to build three businesses at once. Founded in 2021 by Amit Chawla and Shreeram Ramanathan, the startup began purely as a financing solution for pharmaceutical retailers and distributors.
But as the founders dug deeper, they spotted a bigger gap.
"We started with vertical supply chain finance, but as we understood pharma better, we realised there was a huge amount of trade flowing through the sector, but there was no digital spine," said Chawla.
That insight reshaped Fundly into a platform built around three connected pillars
- Commerce (FundlyMart): lets retailers procure pharma stock directly from distributors
- Credit: built into the buying process itself, not sold as a separate loan product
- Payments: infrastructure for collections, payouts, and reconciliation — currently piloting in Pune
This "credit-inside-commerce" approach is the real strategic bet — financing tied to an actual transaction tends to be stickier and lower-risk than standalone lending.
The Numbers Behind the Growth
- Revenue: grew to ~₹30.1 crore in FY25, up from ₹6.6 crore in FY24 — roughly 4.5x growth
- Net loss: widened to ~₹11 crore in FY25, from ₹5.8 crore a year earlier
- Scale: works with ~3,000 distributors across 48 cities; Pune pilot alone covers ~3,000 retailers
The revenue jump is the headline number, but the widening losses matter just as much — they signal Fundly is spending aggressively to build lending and payments infrastructure simultaneously, a pattern common among fintech-style platforms scaling fast.
Where the Capital Is Headed
The fresh funds will go toward expanding commerce, payments, and credit operations across India's pharma supply chain — a scale-up of the existing model, not a pivot. With this round, Fundly has now raised ~$8 million in under three years.
Expert Take: What This Signals
Embedding credit inside a commerce transaction — rather than selling it as a separate product — is a playbook that's worked well in agri-fintech and B2B retail, but pharma adds real friction: strict regulatory compliance, expiry-linked inventory, and thin distributor margins. The presence of venture debt alongside a widening loss column suggests Fundly is financing growth more aggressively than before, which raises the stakes on how disciplined its credit underwriting is as the book scales. The number worth tracking isn't city count — it's whether the Pune payments pilot proves distributors will actually shift reconciliation onto Fundly's rails, or just use it as a lending channel.
Bottom Line
Fundly.ai is betting that pharma's next disruption isn't another marketplace app — it's the invisible financial plumbing underneath it. Whether that bet pays off depends on how fast the Pune pilot scales, and whether growth can outrun the widening losses.
